Adjuvanted influenza vaccines

References

• van Essen GA, Palache AN, Forleo E, Fedson DS. Influenza vaccination in 2000: recommendations and vaccine use in 50 developed and rapidly developing countries. Vaccine 2003; 21:1780 - 5; http://dx.doi.org/10.1016/S0264-410X(03)00072-0; PMID: 12686094
   PubMed Web of Science ®Google Scholar
• Neuzil KM, Mellen BG, Wright PF, Mitchel EF Jr., Griffin MR. The effect of influenza on hospitalization, outpatient visits, and courses of antibiotic use. N Engl J Med 2000; 342:225 - 31; http://dx.doi.org/10.1056/NEJM200001273420401; PMID: 10648763
   PubMed Web of Science ®Google Scholar
• Principi N, Esposito S, Marchisio P, Gasparini R, Crovari P. Socioeconomic impact of influenza on healthy children and their families. Pediatr Infect Dis J 2003; 22:Suppl S207 - 10; http://dx.doi.org/10.1097/01.inf.0000092188.48726.e4; PMID: 14551476
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Prevention and control of influenza with vaccines. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb Mortal Wkly Rep 2010; 59:No. RR-8 1 - 5; PMID: 20075837
   PubMedGoogle Scholar
• European CDC. Seasonal influenza vaccines 2011. Available at http://ecdc.europa.eu/en/healthtopics/seasonal_influenza/vaccines/Pages/influenza_ vaccination.aspx.
   Google Scholar
• Mereckiene J, Cotter S, D'Ancona F, Giambi C, Nicoll A, Levy-Bruhl D, et al. Differences in national influenza vaccination policies across the European Union, Norway and Iceland 2008-2009. Euro Surveill 2010; 15:44; PMID: 21087586
   PubMedGoogle Scholar
• Esposito S, Marchisio P, Principi N. The global state of influenza in children. Pediatr Infect Dis J 2008; 27:Suppl S149 - 53; http://dx.doi.org/10.1097/INF.0b013e31818a542b; PMID: 18955890
   PubMedGoogle Scholar
• Piedra PA, Glezen WP. Influenza in children: epidemiology, immunity, and vaccines. Semin Pediatr Infect Dis 1991; 2:140 - 6
   Google Scholar
• Palache AM, Beyer WE, Lüchters G, Völker R, Sprenger MJ, Masurel N. Influenza vaccines: the effect of vaccine dose on antibody response in primed populations during the ongoing interpandemic period. A review of the literature. Vaccine 1993; 11:892 - 908; http://dx.doi.org/10.1016/0264-410X(93)90375-8; PMID: 8212834
   PubMed Web of Science ®Google Scholar
• Principi N, Esposito S, Marchisio P. Present and future of influenza prevention in pediatrics. Expert Opin Biol Ther 2011; 11:641 - 53; http://dx.doi.org/10.1517/14712598.2011.562495; PMID: 21366499
   PubMed Web of Science ®Google Scholar
• Leroux-Roels G. Unmet needs in modern vaccinology: adjuvants to improve the immune response. Vaccine 2010; 28:Suppl. 3 C25 - 36; http://dx.doi.org/10.1016/j.vaccine.2010.07.021; PMID: 20713254
   PubMed Web of Science ®Google Scholar
• Nauta JJ, Beyer WEP, Osterhaus ADME. On the relationship between antibody response to influenza vaccination, seroprotection and clinical protection from influenza. Biologicals 2009; 37:216 - 21; http://dx.doi.org/10.1016/j.biologicals.2009.02.002; PMID: 19268607
   PubMed Web of Science ®Google Scholar
• Coudeville L, Bailleux F, Riche B, Megas F, Andre P, Ecochard R. Relationship between haemoagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a Bayesian random-effects model. BMC Med Res Methodol 2010; 10:18; PMID: 20210985
   PubMed Web of Science ®Google Scholar
• Beyer WEP, Nauta JJP, Palache AM, Giezeman KM, Osterhaus ADME. Immunogenicity and safety of inactivated influenza vaccines in primed population: a systematic literature review and meta-analysis. Vaccine 2011; Epub May 30.
   Google Scholar
• Morefield GL, Sokolovska A, Jiang D, Hogen Esch H, Robinson JP, Hem SL. Role of aluminum-containing adjuvants in antigen internalization by dendritic cells in vitro. Vaccine 2005; 23:1588 - 95; http://dx.doi.org/10.1016/j.vaccine.2004.07.050; PMID: 15694511
   PubMed Web of Science ®Google Scholar
• Eisenbarth SC, Colegio OR, O'Connor W, Sutterwala FS, Flavell RA. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 2008; 453:1122 - 6; http://dx.doi.org/10.1038/nature06939; PMID: 18496530
   PubMed Web of Science ®Google Scholar
• Eickhoff TC, Myers MG. Workshop summary: aluminum in vaccines. Vaccine 2002; 20:Suppl. 3 S1 - 4; http://dx.doi.org/10.1016/S0264-410X(02)00163-9; PMID: 12184358
   PubMed Web of Science ®Google Scholar
• Jefferson T, Rudin M, Di Pietrantoni C. Adverse events after immunization with aluminium- containing DTP vaccines: systematic review of the evidence. Lancet Infect Dis 2004; 4:84 - 90; http://dx.doi.org/10.1016/S1473-3099(04)00927-2; PMID: 14871632
   PubMed Web of Science ®Google Scholar
• Podda A, Del Giudice G. MF-59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile. Expert Rev Vaccines 2003; 2:197 - 204; http://dx.doi.org/10.1586/14760584.2.2.197; PMID: 12899571
   PubMedGoogle Scholar
• Garçon N, Chomez P, Van Mechelen M. GlaxoSmithKline Adjuvant System in vaccines: concepts, achievement and perspectives. Expert Rev Vaccines 2007; 6:723 - 9; http://dx.doi.org/10.1586/14760584.6.5.723; PMID: 17931153
   PubMed Web of Science ®Google Scholar
• Coffman RL, Sher A, Seder RA. Vaccine adjuvants: putting innate immunity to work. Immunity 2010; 33:492 - 503; http://dx.doi.org/10.1016/j.immuni.2010.10.002; PMID: 21029960
   PubMed Web of Science ®Google Scholar
• Baldo V, Baldovin T, Floreani A, Carraro AM, Trivello R, Family Medicine Group of Pianiga. MF59-adjuvanted influenza vaccine confers superior immunogenicity in adult subjects (18-60 years of age) with chronic diseases who are at risk of post-influenza complications. Vaccine 2007; 25:3955 - 61; http://dx.doi.org/10.1016/j.vaccine.2007.02.045; PMID: 17383057
   PubMed Web of Science ®Google Scholar
• Podda A. The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine 2001; 19:2673 - 80; http://dx.doi.org/10.1016/S0264-410X(00)00499-0; PMID: 11257408
   PubMed Web of Science ®Google Scholar
• Gasparini R, Pozzi T, Montomoli E, Fragapane E, Senatore F, Minutello M, et al. Increased immunogenicity of the MF59-adjuvanted influenza vaccine compared to a conventional subunit vaccine in elderly subjects. Eur J Epidemiol 2001; 17:135 - 40; http://dx.doi.org/10.1023/A:1017919305501; PMID: 11599686
   PubMed Web of Science ®Google Scholar
• Squarcione S, Sgricia S, Biasio LR, Perinetti E. Comparison of the reactogenicity and immunogenicity of a split and a subunit-adjuvanted influenza vaccine in elderly subjects. Vaccine 2003; 21:1268 - 74; http://dx.doi.org/10.1016/S0264-410X(02)00401-2; PMID: 12559808
   PubMed Web of Science ®Google Scholar
• Banzhoff A, Nacci P, Podda A. A new MF59-adjuvanted influenza vaccine enhanced the immune response in the elderly with chronic diseases: results from an immunogenicity meta-analysis. Gerontology 2003; 49:177 - 84; http://dx.doi.org/10.1159/000069172; PMID: 12679609
   PubMed Web of Science ®Google Scholar
• Vesikari T, Pellegrini M, Karvonen A, Groth N, Borkowski A, O'Hagan DT, et al. Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant. Pediatr Infect Dis J 2009; 28:563 - 71; http://dx.doi.org/10.1097/INF.0b013e31819d6394; PMID: 19561422
   PubMed Web of Science ®Google Scholar
• Vesikari T, Groth N, Karvonen A, Borkowski A, Pellegrini M. MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination. Vaccine 2009; 27:6291 - 5; http://dx.doi.org/10.1016/j.vaccine.2009.02.004; PMID: 19840662
   PubMed Web of Science ®Google Scholar
• Cheong HJ, Song JY, Heo JY, Noh JY, Choi WS, Park DW, et al. Immunogenicity and safety of influenza A/H1N1 2009 inactivated split-virus vaccine in young and older adults: MF59 adjuvanted vaccine versus non adjuvanted vaccine. Clin Vaccine Immunol 2011; Epub Jun 29.
   Google Scholar
• Clark TW, Pareek M, Hoschler K, Dillon H, Nicholson KG, Groth N, et al. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N Engl J Med 2009; 361:2424 - 35; http://dx.doi.org/10.1056/NEJMoa0907650; PMID: 19745215
   PubMed Web of Science ®Google Scholar
• Arguedas A, Soley C, Abdelnour A, Sales V, Lindert K, Della Cioppa G, et al. Assessment of the safety, tolerability and kinetics of the immune response to A/H1N1v vaccine formulations with and without adjuvant in healthy pediatric subjects from 3 through 17 years of age. Hum Vaccin 2011; 7:58 - 66; http://dx.doi.org/10.4161/hv.7.1.13411; PMID: 21285531
   PubMed Web of Science ®Google Scholar
• Elkayam O, Amir S, Mendelson E, Schwaber M, Grotto I, Wollman J, et al. Efficacy and safety of vaccination against pandemic 2009 influenza A (H1N1) virus among patients with rheumatic diseases. Arthritis Care Res (Hoboken) 2011; 63:1062 - 7; http://dx.doi.org/10.1002/acr.20465; PMID: 21425247
   PubMed Web of Science ®Google Scholar
• Esposito S, Pugni L, Daleno C, Ronchi A, Valzano A, Serra D, et al. Influenza A/H1N1 MF59-adjuvanted vaccine in preterm and term children aged 6 to 23 months. Pediatrics 2011; 127:e1161 - 8; http://dx.doi.org/10.1542/peds.2010-1920; PMID: 21464195
   PubMed Web of Science ®Google Scholar
• Khurana S, Verma N, Yewdell JW, Hilbert AK, Castellino F, Lattanzi M, et al. MF59 Adjuvant Enhances Diversity and Affinity of Antibody-Mediated Immune Response to Pandemic Influenza Vaccines. Sci Transl Med 2011; 3:85ra48; http://dx.doi.org/10.1126/scitranslmed.3002336; PMID: 21632986
   PubMed Web of Science ®Google Scholar
• Beran J, Abdel-Messih IA, Raupachova J, Hobzova L, Fragapane E. A phase III, randomized, open-label study to assess the tolerability and immunogenicity of an H5N1 influenza vaccine administered to healthy adults with a 1-, 2-, 3-, or 6-week interval between first and second doses. Clin Ther 2010; 32:2186 - 97; http://dx.doi.org/10.1016/S0149-2918(11)00024-5; PMID: 21316535
   PubMed Web of Science ®Google Scholar
• Vesikari T, Karvonen A, Tilman S, Barkowski A, Montomoli E, Banzhoff A, et al. Immunogenicity and safety of MF59-adjuvanted H5N1 influenza vaccine from infancy to adolescence. Pediatrics 2010; 126:e762 - 70; http://dx.doi.org/10.1542/peds.2009-2628; PMID: 20819892
   PubMed Web of Science ®Google Scholar
• Stephenson I, Gust I, Kierry MP, Pervikov Y. Development and evolution of pandemic influenza vaccines. Lancet Infect Dis 2006; 6:71 - 2; http://dx.doi.org/10.1016/S1473-3099(06)70364-4; PMID: 16439326
   PubMed Web of Science ®Google Scholar
• Martin JT. Development of an adjuvant to enhance the immune response to influenza vaccine in the elderly. Biologicals 1997; 25:209 - 13; http://dx.doi.org/10.1006/biol.1997.0086; PMID: 9236054
   PubMed Web of Science ®Google Scholar
• Iob A, Brianti G, Zamparo E, Gallo T. Evidence of increased clinical protection of an MF59-adjuvant influenza vaccine compared to a non-adjuvant vaccine among elderly residents of long-term care facilities in Italy. Epidemiol Infect 2005; 133:687 - 93; http://dx.doi.org/10.1017/S0950268805003936; PMID: 16050515
   PubMed Web of Science ®Google Scholar
• Esposito S, Meregalli E, Daleno C, Ghio L, Tagliabue C, Valzano A, et al. An open-label, randomized clinical trial assessing immunogenicity, safety and tolerability of pandemic influenza A/H1N1 MF59-adjuvanted vaccine administered sequentially or simultaneously with seasonal virosomal-adjuvanted influenza vaccine to paediatric kidney transplant recipients. Nephrol Dial Transplant 2011; 26:2018 - 24; http://dx.doi.org/10.1093/ndt/gfq657; PMID: 20974645
   PubMed Web of Science ®Google Scholar
• Esposito S, D'Angelo E, Daleno C, Peia F, Scala A, Serra D, et al. Immunogenicity, safety and tolerability of monovalent 2009 pandemic influenza A/H1N1 MF59-adjuvanted vaccine in patients with β-thalassemia major. Vaccine 2010; 28:7825 - 8; http://dx.doi.org/10.1016/j.vaccine.2010.09.058; PMID: 20888873
   PubMed Web of Science ®Google Scholar
• Esposito S, Selicorni A, Daleno C, Valzano A, Cerutti M, Galeone C, et al. Immunogenicity, safety and tolerability of monovalent 2009 pandemic influenza A/H1N1 MF59-adjuvanted vaccine in children and adolescents with Williams or Cornelia De Lange syndrome. Hum Vaccine 2011;7: Epub June 1.
   Google Scholar
• Durando P, Icardi G, Ansaldi F. MF59-adjuvanted vaccine: a safe and useful tool to enhance and broaden protection against seasonal influenza viruses in subjects at risk. Expert Opin Biol Ther 2010; 10:639 - 51; http://dx.doi.org/10.1517/14712591003724662; PMID: 20218923
   PubMed Web of Science ®Google Scholar
• Schultze V, D’Agosto V, Wack A, Novicki D, Zorn J, Hennig R. Safety of MF59 adjuvant. Vaccine 2008; 26:3209 - 22; http://dx.doi.org/10.1016/j.vaccine.2008.03.093; PMID: 18462843
   PubMed Web of Science ®Google Scholar
• Parretta E, Ianniello B, Ferrazin F, Rossi F, Capuano A. Italian post-marketing surveillance for adverse event reports after MF59-adjuvanted H1N1v vaccination. Vaccine 2011; 29:3708 - 13; http://dx.doi.org/10.1016/j.vaccine.2011.02.097; PMID: 21406267
   PubMed Web of Science ®Google Scholar
• Levine PH, Richardson PK, Zolfaghari L, Cleary SD, Geist CE, Potolicchio S, et al. A study of Gulf War veterans with a possible deployment-related syndrome. Arch Environ Occup Health 2006; 61:271 - 8; http://dx.doi.org/10.3200/AEOH.61.6.271-278; PMID: 17967750
   PubMed Web of Science ®Google Scholar
• Lippi G, Targher G, Franchini M. Vaccination, squalene and anti-squalene antibodies: facts or fiction?. Eur J Intern Med 2010; 21:70 - 3; http://dx.doi.org/10.1016/j.ejim.2009.12.001; PMID: 20206873
   PubMed Web of Science ®Google Scholar
• Tsai TF, Crucitti A, Nacci P, Nicolay U, Cioppa GD, Ferguson J, et al. Explorations of clinical trials and pharmacovigilance databases of MF59(®)-adjuvanted influenza vaccines for associated cases of narcolepsy. Scand J Infect Dis 2011; Epub May 2.
   Google Scholar
• Chu DW, Hwang SJ, Lim FS, Oh HM, Thongcharoen P, Yang PC, et al. Immunogenicity and tolerability of an AS03(A)-adjuvanted prepandemic influenza vaccine: a phase III study in a large population of Asian adults. Vaccine 2009; 27:7428 - 35; http://dx.doi.org/10.1016/j.vaccine.2009.07.102; PMID: 19683087
   PubMed Web of Science ®Google Scholar
• Leroux-Roels G. Prepandemic H5N1 influenza vaccine adjuvanted with AS03: a review of the pre-clinical and clinical data. Expert Opin Biol Ther 2009; 9:1057 - 71; http://dx.doi.org/10.1517/14712590903066695; PMID: 19555313
   PubMed Web of Science ®Google Scholar
• Schwarz TF, Horacek T, Knuf M, Damman HG, Roman F, Dramé M, et al. Single dose vaccination with AS03-adjuvanted H5N1 vaccines in a randomized trial induces strong and broad immune responsiveness to booster vaccination in adults. Vaccine 2009; 27:6284 - 90; http://dx.doi.org/10.1016/j.vaccine.2009.01.040; PMID: 19856521
   PubMed Web of Science ®Google Scholar
• Waddington CS, Walker WT, Oeser C, Reiner A, John T, Wilkins S, et al. Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study. BMJ 2010; 340:c2649; http://dx.doi.org/10.1136/bmj.c2649; PMID: 20508026
   PubMed Web of Science ®Google Scholar
• Manuel O, Pascual M, Hoschler K, Giulieri S, Alves D, Ellefsen K, et al. Humoral response to the influenza A H1N1/09 monovalent AS03-adjuvanted vaccine in immunocompromised patients. Clin Infect Dis 2011; 52:248 - 56; http://dx.doi.org/10.1093/cid/ciq104; PMID: 21288852
   PubMed Web of Science ®Google Scholar
• Heijmans S, De Meulemeester M, Reynders P, Giet D, Demanet E, Devresse PY, et al. Immunogenicity profile of a 3.75-μg hemagglutinin pandemic rH5N1 split virion AS03A-adjuvanted vaccine in elderly persons: a randomized trial. J Infect Dis 2011; 203:1054 - 62; http://dx.doi.org/10.1093/infdis/jiq174; PMID: 21450995
   PubMed Web of Science ®Google Scholar
• Carmona A, Omeñaca F, Tejedor JC, Merino JM, Vaman T, Dieussaert I, et al. Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6-35 months. Vaccine 2010; 28:5837 - 44; http://dx.doi.org/10.1016/j.vaccine.2010.06.065; PMID: 20600478
   PubMed Web of Science ®Google Scholar
• Garcia-Sicilia J, Gillard P, Carmona A, Tejedor JC, Aristegui J, Merino JM, et al. Immunogenicity and safety of AS03-adjuvanted H1N1 pandemic vaccines in children and adolescents. Vaccine 2011; 29:4353 - 61; http://dx.doi.org/10.1016/j.vaccine.2011.04.011; PMID: 21504774
   PubMed Web of Science ®Google Scholar
• Skowronski DM, Janjua NZ, De Serres G, Hottes TS, Dickinson JA, Crowcroft N, et al. Effectiveness of AS03 adjuvanted pandemic H1N1 vaccine:case-control evaluation based on sentinel surveillance system in Canada, autumn 2009. BMJ 2011; 342:c7297; http://dx.doi.org/10.1136/bmj.c7297; PMID: 21292718
   PubMed Web of Science ®Google Scholar
• Eurosurveillance editorial team.. Swedish Medical Products Agency publishes report from a case inventory study on Pandemrix vaccination and development of narcolepsy with cataplexy. Euro Surveill2011; 16 pii:19904.
   Google Scholar
• World Health Organization. Global Advisory Committee on Vaccine Safety. Statement on nacolepsy and vaccination. 21 April 2011. Available at: http://www.who.int/vaccine_safety/topics/influenza/pandemic/h1n1_safety_assessing/narcolepsy_statement/en/index.html
   Google Scholar
• Mischler R, Metcalfe IC. Inflexal V a trivalent virosome subunit influenza vaccine: production. Vaccine 2002; 20:Suppl 5 B17 - 23; http://dx.doi.org/10.1016/S0264-410X(02)00512-1; PMID: 12477413
   PubMed Web of Science ®Google Scholar
• Huckriede A, Bungener I, Stegmann T, Daemen T, Medema J, Palache AM, et al. The virosomal concept for influenza vaccine. Vaccine 2005; 23:S26 - 38; http://dx.doi.org/10.1016/j.vaccine.2005.04.026; PMID: 16026906
   PubMed Web of Science ®Google Scholar
• Calcagnile S, Zuccotti GV. The virosomal adjuvanted influenza vaccine. Expert Opin Biol Ther 2010; 10:191 - 200; http://dx.doi.org/10.1517/14712590903431014; PMID: 20088714
   PubMed Web of Science ®Google Scholar
• Glück R, Mischler R, Finkel B, Que JU, Scarpa B, Cryz SJ Jr.. Immunogenicity of new virosome influenza vaccine in elderly people. Lancet 1994; 344:160 - 3; http://dx.doi.org/10.1016/S0140-6736(94)92758-8; PMID: 7912766
   PubMed Web of Science ®Google Scholar
• Conne P, Gauthey L, Vernet P, Althaus B, Que JU, Finkel B, et al. Immunogenicity of trivalent subunit versus virosome-formulated influenza vaccines in geriatric patients. Vaccine 1997; 15:1675 - 9; http://dx.doi.org/10.1016/S0264-410X(97)00087-X; PMID: 9364699
   PubMed Web of Science ®Google Scholar
• Pregliasco F, Mensi C, Serpilli W, Speccher L, Masella P, Belloni A. Immunogenicity and safety of three commercial influenza vaccines in institutionalized elderly. Aging 2001; 13:38 - 43; PMID: 11292151
   PubMedGoogle Scholar
• Baldo V, Menegon T, Bonello C, Floreani A, Trivello R. Comparison of three different influenza vaccines in institutionalised elderly. Vaccine 2001; 19:3472 - 5; http://dx.doi.org/10.1016/S0264-410X(01)00060-3; PMID: 11348713
   PubMed Web of Science ®Google Scholar
• Rosenkrands I, Vingsbo-Lundberg C, Bundgaard TJ, Lindenstrøm T, Enouf V, van der Werf S, et al. Enhanced humoral and cell-mediated immune responses after immunization with trivalent influenza vaccine adjuvanted with cationic liposomes. Vaccine 2011; Epub Jun 29.
   Google Scholar
• Even-Or O, Samira S, Rochlin E, Balasingam S, Mann AJ, Lambkin-Williams R, et al. Immunogenicity, protective efficacy and mechanism of novel CCS adjuvanted influenza vaccine. Vaccine 2010; 28:6527 - 41; http://dx.doi.org/10.1016/j.vaccine.2010.04.011; PMID: 20412874
   PubMed Web of Science ®Google Scholar
• Tremblay MH, Majeau N, Gagne´ ME, Lecours K, Morin H, Duvignaud JB, et al. Effect of mutations K97A and E128A on RNA binding and self assembly of papaya mosaic potexvirus coat protein. FEBS J 2006; 273:14 - 25; http://dx.doi.org/10.1111/j.1742-4658.2005.05033.x; PMID: 16367744
   PubMed Web of Science ®Google Scholar
• Denis J, Majeau N, Acosta-Ramirez E, Savard C, Be’dard MC, Simard S, et al. Immunogenicity of papaya mosaic virus-like particles fused to a hepatitis C virus epitope: evidence for the critical function of multimerization. Virology 2007; 363:59 - 68; http://dx.doi.org/10.1016/j.virol.2007.01.011; PMID: 17320136
   PubMed Web of Science ®Google Scholar
• Denis J, Acosta-Ramirez E, Zhao Y, Hamelin ME, Koukavica I, Baz M, et al. Development of a universal influenza A vaccine based on the M2e peptide fused to the papaya mosaic virus (PapMV) vaccine platform. Vaccine 2008; 26:3395 - 403; http://dx.doi.org/10.1016/j.vaccine.2008.04.052; PMID: 18511159
   PubMed Web of Science ®Google Scholar
• Savard C, Guérin A, Drouin K, Bolduc M, Laliberté-Gagné ME, Dumas MC, et al. Improvement of the Trivalent Inactivated Flu Vaccine Using PapMV Nanoparticles. PLoS ONE 2011; 6:e21522; http://dx.doi.org/10.1371/journal.pone.0021522; PMID: 21747909
   PubMedGoogle Scholar
• Coutelier JP, van der Logt JT, Heessen FW, Warnier G, Van Snick J. IgG2a restriction of murine antibodies elicited by viral infections. J Exp Med 1987; 165:64 - 9; http://dx.doi.org/10.1084/jem.165.1.64; PMID: 3794607
   PubMed Web of Science ®Google Scholar
• Hocart MJ, Mackenzie JS, Stewart GA. The immunoglobulin G subclass responses of mice to influenza A virus: the effect of mouse strain, and the neutralizing abilities of individual protein A-purified subclass antibodies. J Gen Virol 1989; 70:2439 - 48; http://dx.doi.org/10.1099/0022-1317-70-9-2439; PMID: 2778440
   PubMed Web of Science ®Google Scholar
• Mallick AI, Parvizi P, Read LR, Nagy E, Berhboudi S. Enhancement of immunogenicity of a virosome-based avian influenza vaccine in chickens by incorporating CpG-ODN. Vaccine 2011; 29:1657 - 65; http://dx.doi.org/10.1016/j.vaccine.2010.12.046; PMID: 21195078
   PubMed Web of Science ®Google Scholar
• Klinman DM, Yi AK, Beaucage SL, Conover J, Krieg AM. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc Natl Acad Sci USA 1996; 93:2879 - 83; http://dx.doi.org/10.1073/pnas.93.7.2879; PMID: 8610135
   PubMed Web of Science ®Google Scholar
• Mallick AI, Parvizi P, Read LR, Nagy E, Behboudi S, Sharif S. Enhancement of immunogenicity of a virosome-based avian influenza vaccine in chickens by incorporating CpG-ODN. Vaccine 2011; 29:1657 - 65; http://dx.doi.org/10.1016/j.vaccine.2010.12.046; PMID: 21195078
   PubMed Web of Science ®Google Scholar
• Morein B, Sundquist B, Hoglund S, Dalsgaard K, Osterhaus A. Iscom, a novel structure for antigen presentation of membrane proteins from enveloped viruses. Nature 1984; 308:457 - 60; http://dx.doi.org/10.1038/308457a0; PMID: 6709052
   PubMed Web of Science ®Google Scholar
• Maraskovsky E, Schnurr M, Wilson NS, Robson NC, Boyle J, Drane D. Development of prophylactic and therapeutic vaccines using the ISCOMATRIX adjuvant. Immunol Cell Biol 2009; 87:371 - 6; http://dx.doi.org/10.1038/icb.2009.21; PMID: 19381160
   PubMed Web of Science ®Google Scholar
• Davis ID, Chen W, Jackson H, Parente P, Shackleton M, Hopkins W, et al. Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. Proc Natl Acad Sci USA 2004; 101:10697 - 702; http://dx.doi.org/10.1073/pnas.0403572101; PMID: 15252201
   PubMed Web of Science ®Google Scholar
• Brown LE. The role of adjuvants in vaccines for seasonal and pandemic influenza. Vaccine 2010; 28:8043 - 5; http://dx.doi.org/10.1016/j.vaccine.2010.09.024; PMID: 20849874
   PubMed Web of Science ®Google Scholar
• Sanders MT, Deliyannis C, Pearse MJ, McNamara MK, Brown LE. Single dose intranasal immunization with ISCOMATRIX vaccines to elicit antibody-mediated clearance of influenza virus requires delivery to the lower respiratory tract. Vaccine 2009; 27:2475 - 82; http://dx.doi.org/10.1016/j.vaccine.2009.02.054; PMID: 19368789
   PubMed Web of Science ®Google Scholar
• Song L, Nakaar V, Kavita U, Price A, Huleatt J, Tang J, et al. Efficacious recombinant influenza vaccines produced by high yield bacterial expression: a solution to global pandemic and seasonal needs. PLoS ONE 2008; 3:e2257; http://dx.doi.org/10.1371/journal.pone.0002257; PMID: 18493310
   PubMed Web of Science ®Google Scholar
• Liu G, Tarbet B, Song L, Reiserova L, Weaver B, Chen Y, et al. Immunogenicity and efficacy of flagellin-fused vaccine candidates targeting 2009 pandemic H1N1 influenza in mice. PLoS ONE 2011; 6:e20928; http://dx.doi.org/10.1371/journal.pone.0020928; PMID: 21687743
   PubMed Web of Science ®Google Scholar
• Taylor DN, Treanor JJ, Strout C, Johnson C, Fitzgerald T, Kavita U, et al. Induction of a potent immune response in the elderly using the TLR-5 agonist, flagellin, with a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125, STF2.HA1 SI). Vaccine 2011; 29:4897 - 902; http://dx.doi.org/10.1016/j.vaccine.2011.05.001; PMID: 21596084
   PubMed Web of Science ®Google Scholar
• Didierlaurent AM, Morel S, Lockman L, Giannini SL, Bisteau M, Carlsen H, et al. AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J Immunol 2009; 183:6186 - 97; http://dx.doi.org/10.4049/jimmunol.0901474; PMID: 19864596
   PubMed Web of Science ®Google Scholar